Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Shaftesbury Down 13% Amid Fundraise Plans

Thu, 22nd Oct 2020 11:06

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.

----------

FTSE 250 - LOSERS

----------

Shaftesbury, down 13%, and Capital & Counties, down 11%. Shaftesbury said it intends to raise GBP307 million via the issue of new shares to ensure financial flexibility to navigate the "unprecedented" challenges created by the Covid-19 pandemic. Current market capitalisation is GBP1.33 billion. Capital & Counties Properties said it will participate in the Shaftesbury fundraise by providing GBP65 million.

----------

Moneysupermarket, down 5.7%, the price comparison website firm said revenue dropped across all of its businesses in the third quarter, with the company blaming the "disruption" caused by the pandemic. In the three months to September 30, Moneysupermarket's total revenue dropped 16% year on year to GBP85.1 million.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Premier African Minerals up 19%. The southern Africa-focused miner said it has settled all amounts it owes to directors, employees and other creditors, amounting to GBP600,057 of shares. Along with the GBP1.1 million placing, completed on Wednesday, the company is now debt free.

----------

OPG Power Ventures, up 16%. The Indian power plant operator said revenue in the year ended March 31 rose 9.5% to GBP154.0 million from GBP140.6 million. Pretax profit slipped 14% to GBP14.5 million from GBP16.9 million.

----------

4D Pharma up 16% after it proposed a merger with special-purpose acquisition company Longevity Acquisition Corp. Longevity shareholders will hold 13% of the enlarged firm. The deal values 4D Pharma shares at GBP1.10 each - an 18% premium to its GBP0.932 closing price on Wednesday - GBP144.5 million altogether. 4D's current market capitalisation is GBP141.1 million. The enlarged company will also launch an American depositary receipts programme, eyeing a Nasdaq listing.

----------

Pendragon up 12%, the motor retailer said it delivered a "very strong" third quarter, with total revenue down 14% annually, but up 1.2% like-for-like. Underlying pretax profit surged to GBP27.3 million from GBP3.0 million a year earlier. Opts not to reinstate annual guidance, however.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Kibo Energy, down 12% after the Africa-focused energy firm posted a narrowed loss in the six months to June 30. Its pretax loss slimmed to GBP1.3 million from GBP1.8 million, though like last year, it generated no revenue. Noted that Covid-19 has caused delays to its project development targets.

----------

Thalassa Holdings, dropped 12% after a regulatory filing showed investor Lombard Odier Asset Management Ltd trimmed its stake in the British Virgin Islands-based investment holding company to 1.4% from 14% during a transaction on Wednesday.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
24 May 2021 09:42

More positive data reported from 4D Pharma trial of 'Blautix'

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced additional positive data from its completed phase 2 trial of 'LBP Blautix' on Monday, in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).

Read more
24 May 2021 09:20

4d Pharma posts more "positive" results from Blautix probe

4d Pharma posts more "positive" results from Blautix probe

Read more
17 May 2021 16:05

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
19 Apr 2021 10:50

4D Pharma forms partnership with Parkinson's UK to improve treatments

4D Pharma forms partnership with Parkinson's UK to improve treatments

Read more
16 Apr 2021 15:17

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

DIRECTOR DEALINGS: Tesco chair invests GBP100,000; Dechra exec sells

Read more
1 Apr 2021 12:00

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

TRADING UPDATES: 4D Pharma loss widens on rise in administrative costs

Read more
22 Mar 2021 09:25

4D Pharma completes reversal into Nasdaq listing via US Spac

4D Pharma completes reversal into Nasdaq listing via US Spac

Read more
17 Mar 2021 18:40

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

TRADING UPDATES: Ceres Power eyes move to Main Market by mid-2022

Read more
11 Mar 2021 16:11

UK shareholder meetings calendar - next 7 days

UK shareholder meetings calendar - next 7 days

Read more
1 Mar 2021 16:41

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

EXECUTIVE CHANGES: New CFOs for Sensyne, Focusrite, Bango, 4D Pharma

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 14:33

4D Pharma taps John Beck as its new finance chief

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced the appointment of John Beck as its chief financial officer and member of its management team on Monday.

Read more
1 Mar 2021 10:14

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

IN BRIEF: 4D Pharma appoints former Ritter finance chief as own CFO

Read more
26 Feb 2021 10:26

4D Pharma Registration Statements Effective; Longevity Buy Progresses

4D Pharma Registration Statements Effective; Longevity Buy Progresses

Read more
8 Feb 2021 16:25

4D Pharma inks collaboration with Merck and Pfizer

(Sharecast News) - Biotherapeutics developer 4D Pharma announced a clinical trial collaboration and supply agreement with Merck and Pfizer on Monday, for 'Bavencio', or avelumab).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.